https://ir.ymlib.yonsei.ac.kr/handle/22282913/168862 2026-06-15T21:54:16Z 2026-06-15T21:54:16Z Kang, Sungwoo Na, Han Kyu Yoon, So Hoon Kim, Han-Kyeol Ryu, Young Hoon Lee, Hye Sun Yoo, Han Soo Lyoo, Chul Hyoung 유한수 https://ir.ymlib.yonsei.ac.kr/handle/22282913/211443 2026-03-25T03:03:03Z 2026-07-01T00:00:00Z

Title: Interplay of age-sensitive cortical vulnerability and dopaminergic degeneration in clinical manifestations of Parkinson's disease Authors: Kang, Sungwoo; Na, Han Kyu; Yoon, So Hoon; Kim, Han-Kyeol; Ryu, Young Hoon; Lee, Hye Sun; Yoo, Han Soo; Lyoo, Chul Hyoung; 유한수 Abstract: To identify the pattern of cortical atrophy variation in Parkinson's disease (PD) and its contribution to clinical manifestations beyond dopaminergic dysfunction, 45 healthy controls (HCs) underwent MRI, and 222 participants with PD additionally underwent dopamine transporter (DAT)-PET, Unified PD Rating Scale (UPDRS), and neuropsychological tests. Using principal component analysis in PD, a single pattern in cortical thickness (PC1PD) was identified. Linear regressions models were applied to investigate the effects of PC1PD and putaminal DAT (DAT-P) on parkinsonism, and PC1PD and caudate DAT (DAT-C) on cognition. PC1PD accounted for more than 80% of total cortical variance and showed a strong negative correlation with age. The spatial pattern of PC1PD was similar to that of PC1 derived from HCs, but its age-related association was more pronounced in PD. Independent of DAT-P, lower PC1PD was associated with higher UPDRS motor score and showed a synergistic significant interaction with DAT-P on the axial subscore. Independent of DAT-C, lower PC1PD was associated with worse performance in global cognition, language, and executive functions, with synergistic interaction with DATC on global cognition and executive function. The associations of PC1PD with UPDRS motor scores, general cognition, and executive function were stronger in older participants, indicating that aging amplifies the clinical effect of PC1PD. PC1PD represents an age-sensitive cortical vulnerability axis whose expression is amplified in PD, and its interplay with dopaminergic depletion and aging contributes to axial motor symptoms and executive dysfunction in PD.

2026-07-01T00:00:00Z Lee, Hyojin Kim, Chang Gon Han, Sookyeong Park, Su Kyoung Yoon, Hong In Kim, Kyung Hwan Shim, Hyo Sup Hong, Min Hee Yeo, Ja Hyun Kim, Sangwoo Hwang, Sang Hyun Kim, Hye Ryun Hong, Namki 여자현 여자현 https://ir.ymlib.yonsei.ac.kr/handle/22282913/212235 2026-05-15T00:12:54Z 2026-04-01T00:00:00Z

Title: Sarcopenia Predicts Outcome After Chemoimmunotherapy, Not Chemotherapy, in Advanced Lung Cancer: Single-Centre Retrospective Study Authors: Lee, Hyojin; Kim, Chang Gon; Han, Sookyeong; Park, Su Kyoung; Yoon, Hong In; Kim, Kyung Hwan; Shim, Hyo Sup; Hong, Min Hee; Yeo, Ja Hyun; Kim, Sangwoo; Hwang, Sang Hyun; Kim, Hye Ryun; Hong, Namki; 여자현; 여자현 Abstract: Background Sarcopenia, characterized by progressive loss of skeletal muscle mass, is prevalent in patients with non-small cell lung cancer (NSCLC). While sarcopenia has been associated with poor prognosis in multiple types of cancer, its predictive role in the context of first-line treatment combining PD-(L)1 inhibitors with platinum-based chemotherapy (CITx) remains unclear in advanced NSCLC.Methods In a single-centre retrospective cohort, patients with advanced NSCLC without actionable genomic alterations who received either CITx (n = 552) or platinum-doublet chemotherapy alone (CTx; n = 622) were analysed. Sarcopenia was defined on the Martin's computed tomography-derived skeletal muscle index definition. Progression-free survival (PFS) and overall survival (OS) were assessed. Interaction between sarcopenia and treatment modality was explored.Results Sarcopenia was observed in 49.5% of patients. The presence of sarcopenia was associated with worse outcomes in overall patients (median OS: 9.4 vs. 11.4 months; HR 1.22, 95% CI 1.08-1.39). When stratified by treatment groups, sarcopenia was significantly associated with higher risk of progression (adjusted HR 1.23, 95% CI 1.01-1.49) and death (adjusted HR 1.42, 95% CI 1.16-1.74) in CITx-treated patients, whereas no such association was observed in the CTx group. The interaction between sarcopenia and treatment type was significant for both PFS (p = 0.041) and OS (p = 0.022).Conclusions Sarcopenia is a predictive biomarker for inferior outcomes in patients with advanced NSCLC treated with CITx, but not with CTx. Assessment of skeletal muscle mass can help identify patients at risk for suboptimal response to CITx. This study provides grounds for future exploration in interventions targeting sarcopenia and cachexia to enhance clinical outcomes in advanced cancer patients.

2026-04-01T00:00:00Z Lee, Jae Won Lee, Jae-Hoon Cho, Eun-Suk Shin, Su-Jin Lee, Hye Sun Lee, Kang Young Kang, Jeonghyun https://ir.ymlib.yonsei.ac.kr/handle/22282913/211625 2026-03-31T01:20:45Z 2026-03-01T00:00:00Z

Title: Association of body composition and nutritional status with survival in stage IV colorectal cancer patients who underwent resection: a retrospective cohort study Authors: Lee, Jae Won; Lee, Jae-Hoon; Cho, Eun-Suk; Shin, Su-Jin; Lee, Hye Sun; Lee, Kang Young; Kang, Jeonghyun Abstract: Purpose: Although host body composition, nutritional and systemic inflammatory status have been suggested to have an impact on prognosis in patients with colorectal cancer (CRC), their impact on patients with stage IV CRC remains unclear. This study investigated the prognostic effects of those parameters in patients initially diagnosed with stage IV CRC who underwent surgery. Methods: Patients with stage IV CRC who underwent surgery were selected. Preoperative computed tomography images were evaluated for skeletal muscle index, skeletal muscle density (SMD), visceral fat area (VFA), and subcutaneous fat area (SFA). For nutritional status and systemic inflammation, prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) were used. The Cox proportional hazard model was used to evaluate the prognostic significance of progression-free survival (PFS) after adjustment for the other covariates in the model. Results: Data of 134 patients with stage IV CRC who underwent surgery between January 2005 and February 2014 were included. SMD, VFA, SFA, PNI, NLR, LMR, and PLR were associated with PFS in the univariable analysis. In the multivariable analysis, SFA (hazard ratio [HR], 0.612; 95% confidence interval [CI], 0.389-0.961; P = 0.033), and PNI (HR, 0.536; 95% CI, 0.345-0.832; P = 0.005) were identified to be independent prognostic factors for PFS. Conclusion: SFA and PNI both demonstrated prognostic significance in patients with stage IV CRC. Accordingly, we believe further studies are warranted to determine whether incorporating these factors can aid in surgical decision-making for stage IV CRC patients.

2026-03-01T00:00:00Z Kang, Chan Woo Hong, Zhen-Yu Oh, Ju Hun Farh, Mohamed El-Agamy Wang, Eun Kyung Lee, Soohyun Kang, Un Ho Nam, Jung Ho Lee, Yang Jong Shin, Hyeju Kim, Ye Bin Jeon, Hyeonuk Jeong, Jae Woong Kim, Doyeon Kim, Jung Seung Hong, Seung Soo Park, Jong-Pil Cho, Hyo Je Fang, Sungsoon Kim, Hyongbum Henry Cho, Arthur Lim, Byung Kook Sohn, Insuk Ku, Cheol Ryong 홍승수 구철룡 https://ir.ymlib.yonsei.ac.kr/handle/22282913/211492 2026-03-25T07:51:52Z 2026-02-01T00:00:00Z

Title: Atypical protein kinase C activation drives intestinal glucose excretion in diabetes mellitus Authors: Kang, Chan Woo; Hong, Zhen-Yu; Oh, Ju Hun; Farh, Mohamed El-Agamy; Wang, Eun Kyung; Lee, Soohyun; Kang, Un Ho; Nam, Jung Ho; Lee, Yang Jong; Shin, Hyeju; Kim, Ye Bin; Jeon, Hyeonuk; Jeong, Jae Woong; Kim, Doyeon; Kim, Jung Seung; Hong, Seung Soo; Park, Jong-Pil; Cho, Hyo Je; Fang, Sungsoon; Kim, Hyongbum Henry; Cho, Arthur; Lim, Byung Kook; Sohn, Insuk; Ku, Cheol Ryong; 홍승수; 구철룡 Abstract: Intestinal glucose excretion, defined as increased intestinal serum glucose uptake and secretion into the lumen, influences bariatric surgery-associated glycaemic control. Here, we investigate molecular mechanisms that activate intestinal glucose excretion. We evaluate altered transcriptomes in variable intestinal glucose excretion models and big data-based drug discovery systems. We show that protein kinase C (PKC) activation mimics transcriptome alterations observed during intestinal glucose excretion. Among PKC subfamilies, atypical PKC (aPKC) facilitates glucose transporter 1 (GLUT1)-mediated intestinal glucose excretion without inducing oncogenic proliferation. Intestinal aPKC activation via transposon expression vector induces serum glucose uptake into intestinal tissues and excretion into the lumen. Prostratin, a non-tumorigenic phorbol ester, activates aPKC and induces a similar effect on intestinal glucose excretion. We identify the prostratin and aPKC/GLUT1 signalling pathways as putative targets for treating diabetes, providing insights into the future development of antidiabetic and weight-loss drugs.

2026-02-01T00:00:00Z